Table 5.

hrHPV genotyping agreement in the total study population between OncoPredict HPV® SCR and GP5+/6+ PCR‐LMNX

HPV type	−/−a	+/+a	−/+a	+/−a	General agreement (95% CI)	Kappa (95% CI)
HPV 16	1135	93	1	10	99% (98%–100%)	0.94 (0.90–0.98)
HPV 18	1198	26	2	13	99% (98%– 99%)	0.77 (0.66–0.88)
Other hrHPVb	948	236	37	18	96% (94%–97%)	0.87 (0.83–0.90)

Note: Color legend (adapted from Landis & Koch ³¹ ) for the levels of agreement: dark green (1.00 ≥ K > 0.80): excellent; light green (0.80 ≥ K > 0.60): good; yellow (0.60 ≥ _K > 0.40): moderate; orange (0.40 ≥ _ K > 0.20): fair; red (0.20 ≥ K > 0.00): poor.

Abbreviations: HPV, human papillomavirus; hrHPV, high‐risk HPV.

^a −/− both tests are concordantly negative; +/+ both tests are concordantly positive; −/+ OncoPredict HPV® SCR negative, GP5+/6+ LMNX positive; +/− OncoPredict HPV® SCR positive, GP5+/6+ LMNX negative.

^b Other hrHPV includes the aggregate of HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 for OncoPredict HPV® SCR whilst GP5+/6+ LMNX also includes the additional HPV types: −66, −26, −53, −73, and −82.